CoChat

Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment

Open access
Sharick, Joe T., Walsh, Christine M., Sprackling, Carley M., Pasch, Cheri A., Pham, Dan L., Esbona, Karla, Choudhary, Alka, Garcia-Valera, Rebeca, Burkard, Mark E., McGregor, Stephanie M., Matkowskyj, Kristina A., Parikh, Alexander A., Meszoely, Ingrid M., Kelley, Mark C., Tsai, Susan, Deming, Dustin A., Skala, Melissa C. · 2020 · Frontiers in Oncology
Cited by 142

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogeneity. In this study, non-invasive optical metabolic imaging (OMI) of cellular heterogeneity was characterized in breast cancer (BC) and pancreatic cancer (PC) patient-derived organoids. Baseline heterogeneity was analyzed for each patient, demonstrating that single-cell techniques, such as OMI, are required to capture the complete picture of heterogeneity present in a sample. Treatment-induced changes in heterogeneity were also analyzed, further demonstrating that these measurements greatly complement current techniques that only gauge average cellular response. Finally, OMI of cellular heterogeneity in organoids was evaluated as a predictor of clinical treatment response for the first time. Organoids were treated with the same drugs as the patient's prescribed regimen, and OMI measurements of heterogeneity were compared to patient outcome. OMI distinguished subpopulations of cells with divergent and dynamic responses to treatment in living organoids without the use of labels or dyes. OMI of organoids agreed with long-term therapeutic response in patients. With these capabilities, OMI could serve as a sensitive high-throughput tool to identify optimal therapies for individual patients, and to develop new effective therapies that address cellular heterogeneity in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2020.00553

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 142

Metadata

Authors
Sharick, J. T., Walsh, C. M., Sprackling, C. M., Pasch, C. A., Pham, D. L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M. E., McGregor, S. M., Matkowskyj, K. A., Parikh, A. A., Meszoely, I. M., Kelley, M. C., Tsai, S., Deming, D. A., & Skala, M. C.
Venue
Frontiers in Oncology
Published
2020-05-15
Volume
10
Pages
553-553
ISSN
2234-943X (ISSN-L)
OpenAlex
W3025063128
Cited by
142
References
14
FWCI
8.63
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. https://app.cochat.ai/papers/10.3389/fonc.2020.00553
The paper
Sharick, J. T., Walsh, C. M., Sprackling, C. M., Pasch, C. A., Pham, D. L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M. E., McGregor, S. M., Matkowskyj, K. A., Parikh, A. A., Meszoely, I. M., Kelley, M. C., Tsai, S., Deming, D. A., & Skala, M. C. (2020). Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.00553

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.